Vanda Pharmaceuticals | VNDA - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Akebia Therapeutics 4.83M 359.32M 2025-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Anika Therapeutics 189.44M 1.76M 2025-09
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Esperion Therapeutics USD 22.64M 585K 2025-12
Halozyme Therapeutics USD 4.91M 615K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 20.6M 217K 2025-12
J&J USD 18M 290M 2025-09
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
Ligand Pharmaceuticals USD 910K 243K 2025-09
Merck USD 412M 85M 2025-12
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 12.14B 12.13B 2025-09
Novartis USD 281M 8M 2025-09
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 252M 2025-12
Takeda JPY 123.63B 40.49B 2025-12
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09
Veracyte USD 2K 1000 2023-12